
ACCURUN® 305 SERIES 400

HCV RNA Positive Quality Control



Health Hazard



ACCURUN[®] 305 SERIES 400 HCV RNA Positive Quality Control

NAME AND INTENDED USE

ACCURUN controls are intended to estimate laboratory testing precision and can be used to detect errors in laboratory testing procedures. ACCURUN[®] 305 HCV RNA Positive Quality Control Series 400 is formulated for use with laboratory tests that detect and quantitate HCV RNA. Additional controls at different concentrations of HCV RNA are available separately from LGC Clinical Diagnostics. *For In Vitro Diagnostic Use*.

SUMMARY

Frequent testing of independent quality control samples provides the analyst with a means of monitoring the performance of laboratory assays. Routine use of controls enables laboratories to monitor day-to-day test variation, lot-to-lot performance of test kits, and operator variation, and can assist in identifying increases in random or systematic error. A well-designed quality control program can provide added confidence in the reliability of results obtained for unknown specimens. The use of independent controls may provide valuable information concerning laboratory proficiency and kit lot variation that may affect assay sensitivity¹.

PRINCIPLES OF THE PROCEDURE

ACCURUN 305 HCV RNA Positive Quality Control Series 400 is designed for use with laboratory testing for the purpose of monitoring test performance. ACCURUN 305 HCV RNA Positive Quality Control Series 400 is manufactured from human serum or plasma reactive for HCV RNA type 1 and nonreactive for HBsAg and antibodies to HIV 1 and HIV 2 and HTLV. ACCURUN controls do not have assigned values. Specific levels of reactivity will vary among different manufacturers' assays, different procedures, different lot numbers, and different laboratories.

REAGENTS

Item No. 2020-0085

5 vials, 4.0 mL pervial

ACCURUN 305 HCV RNA Positive Quality Control Series 400 contains stabilizers and 0.09% sodium azide as preservative.

WARNINGS AND PRECAUTIONS

For In Vitro Diagnostic Use.

CAUTION: Handle ACCURUN controls and all human blood products as though capable of transmitting infectious agents. ACCURUN 305 HCV RNA Positive Quality Control Series 400 is manufactured from human serum or plasma nonreactive for HBsAg and antibodies for HIV 1 and 2 and HTLV with current FDA licensed tests.

Safety Precautions

Use the Centers for Disease Control (CDC) recommended universal precautions for handling ACCURUN and human blood². Do not pipette by mouth; do not smoke, eat or drink in areas where specimens are being handled. Clean any spillage by immediately wiping up with 0.5% sodium hypochlorite solution. Dispose of all specimens, controls and materials used in testing as though they contain infectious agents.

Handling Precautions

Do not use ACCURUN controls beyond the expiration date. Avoid contamination of the controls when opening and closing the vials. To prevent formation of potentially explosive compounds due to reactions of sodium azide and copper or lead pipes, flush waste lines with large quantities of water.

STORAGE INSTRUCTIONS

For maximum stability, ACCURUN 305 HCV RNA Positive Quality Control Series 400 should be stored at -70°C. If preferred, vials may be stored at -20°C for up to six months. To prevent leakage, store vials upright.

INDICATIONS OF REAGENT INSTABILITY OR DETERIORATION

Alterations in physical appearance may indicate instability or deterioration of ACCURUN controls. Solutions that are visibly turbid should be discarded.

PROCEDURE

Materials Provided

ACCURUN 305 HCV RNA Positive Quality Control Series 400 is manufactured from human serum or plasma reactive for HCV RNA genotype 1 and nonreactive for HBsAg and antibodies to HIV 1 and 2 and HTLV.

Materials Required but not Provided

Refer to instructions supplied by manufacturers of the test kits to be used.

Instructions for Use

- Prior to each use, allow the control to reach room temperature and mix by gentle inversion.
 Each vial of ACCURUN 305 should not be used more than three times and must be used within 10 days after first opening.
- Immediately after each use, refrigerate ACCURUN 305 at 2-8°C.
- When the vial is opened for the first time, record the date opened and the expiration date on the vial.
- · To minimize the chance of contamination, discard the vial after first use.

ACCURUN controls should be included in a test run using exactly the same procedure provided by the manufacturer for unknown specimens. ACCURUN controls must NOT be substituted for the positive and negative control reagents provided with manufactured test kits.

Quality Control

Since ACCURUN controls do not have assigned values, it is recommended that each laboratory validate the use of each lot of ACCURUN with each specific assay system prior to its routine use in the laboratory.

INTERPRETATION OF RESULTS

Levels of reactivity of ACCURUN 305 HCV RNA Positive Quality Control Series 400 may vary with different manufacturers' tests and different test kit lots. Since the control does not have an assigned value, the laboratory must establish a range for each lot of ACCURUN 305 HCV RNA Positive Quality Control Series 400. When results for ACCURUN 305 HCV RNA Positive Quality Control Series 400 are outside the established acceptable range of values, it may be an indication of unsatisfactory test performance. Possible sources of error include: deterioration of test kit reagents, operator error, faulty performance of equipment, or contamination of reagents.

LIMITATIONS OF THE PROCEDURE

ACCURUN CONTROLS MUST NOT BE SUBSTITUTED FOR THE POSITIVE AND NEGATIVE CONTROL REAGENTS PROVIDED WITH MANUFACTURED TEST KITS. *TEST PROCEDURES* and *INTERPRETATION OF RESULTS* provided by manufacturers of test kits must be followed closely. Deviations from procedures recommended by test kit manufacturers may produce unreliable results. ACCURUN controls are not calibrators and should not be used for assay calibration. Performance characteristics for ACCURUN 305 HCV RNA Positive Quality Control Series 400 have been established only for HCV RNA. Adverse shipping and storage conditions or use of outdated controls may produce erroneous results.

EXPECTED RESULTS

ACCURUN 305 HCV RNA Positive Quality Control Series 400 DOES NOT HAVE AN ASSIGNED VALUE. Specific levels of reactivity will vary among different manufacturers' assays, different procedures, different lot numbers, and different laboratories. Procedures for implementing a quality assurance program and monitoring test performance on a routine basis must be established by each individual laboratory. Each laboratory should establish its own range of acceptable values. For example, the acceptable range might include all values within 2 standard deviations of the mean of 20 data points obtained in 20 runs over a period of 30 days³.

SPECIFIC PERFORMANCE CHARACTERISTICS

ACCURUN controls are designed for use with laboratory testing for purposes of monitoring assay performance. ACCURUN 305 HCV RNA Positive Quality Control Series 400 is manufactured from human serum or plasma reactive for HCV RNA type 1 and nonreactive for HBsAg and antibodies to HIV 1 and 2 and HTLV. ACCURUN controls do not have assigned values. Specific levels of reactivity will vary among different manufacturers' assays, different procedures, different lot numbers, and different laboratories. Procedures for implementing a quality assurance program and monitoring test performance on a routine basis must be established by each individual laboratory.

REFERENCES

- Green IV GA, Carey RN, Westgard JO, Carten T, Shablesky LA, Achord D, Page E, and Le AV. Quality control for qualitative assays: quantitative QC procedure designed to assure analytical quality required for an ELISA for hepatitis B surface antigen. Clin. Chem. 43:9 1618-1621, 1997.
- Siegel JD, Rhinehart E, Jackson M, Chiarello L, and the Healthcare Infection Control Practices Advisory Committee, 2007 Guideline for Isolation Precautions: Preventing Transmission of Infectious Agents in Healthcare Settings.
- Statistical Quality Control for Quantitative Measurements: Principles and Definitions; Approved Guideline – Second Edition. NCCLS document C24-A2, 1999.

For assistance, contact LGC Clinical DiagnosticsTechnical Support at +1 508.244.6400.